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HIV-infected individuals recently released from incarceration have suboptimal linkage and
engagement in community HIV care. We conducted a study to evaluate an information and
communication technology intervention to increase linkage to community care among HIV-
infected persons recently involved in the criminal justice (CJ) system. Baseline characteris-
tics including risk behaviors and HIV care indicators are reported and stratified by gender.
Methods
We recruited HIV-infected individuals in the District of Columbia jail and persons with a
recent history of incarceration through community and street outreach. Participants com-
pleted a baseline computer-assisted personal interview regarding HIV care and antiretrovi-
ral treatment (ART) adherence, substance use, and sexual behaviors. CD4 and HIV plasma
viral load testing were performed at baseline or obtained through medical records. Data
were analyzed for the sample overall and stratified by gender.
Results
Of 110 individuals, 70% were community-enrolled, mean age was 40 (SD = 10.5), 85%
were Black, and 58% were male, 24% female, and 18% transgender women. Nearly half
(47%) had condomless sex in the three months prior to incarceration. Although drug depen-
dence and hazardous alcohol use were highly prevalent overall, transgender women were
more likely to have participated in drug treatment than men and women (90%, 61%, and
50% respectively; p = 0.01). Prior to their most recent incarceration, 80% had an HIV pro-
vider and 91% had ever taken ART. Among those, only 51% reported90% ART adher-
ence. Fewer women (67%) had received HIV medications during their last incarceration
compared to men (96%) and transgender women (95%; p = 0.001). Although neither was
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statistically significant, transgender women and men had higher proportions of baseline HIV
viral suppression compared to women (80%, 69%, and 48.0% respectively, p>0.05); a
higher proportion of women had a CD4 count200 compared to men and transgender
women (17%, 8% and 5% respectively; p>0.05).
Conclusions
In this study, HIV-infected persons with recent incarceration in Washington, DC reported
important risk factors and co-morbidities, yet the majority had access to HIV care and ART
prior to, during, and after incarceration. Self-reported ART adherence was sub-optimal, and
while there were not statistically significant differences, CJ-involved women appeared to be
at greatest risk of poor HIV outcomes.
Trial registration
Registered on ClinicalTrials.gov on 10/16/2012. Reference number: NCT01721226.
Background
Criminal justice (CJ)-involved persons, defined as persons with a history of incarceration in
prison or jail and persons who have been under community corrections supervision (probation,
parole), are disproportionately impacted by HIV infection. A high prevalence of substance use
disorders, mental health disorders and racial and ethnic health disparities contribute to this
increased burden [1, 2]. CJ populations experience high rates of unstable housing, unemploy-
ment, and poverty, which negatively influence retention in longitudinal HIV care [3]. Incarcera-
tion and subsequent release from a correctional facility have been associated with interruptions
in antiretroviral treatment (ART) [4], loss of viral control [5] and failure to maintain adherence
to ART [4, 6, 7]. Approximately one in seven HIV-infected persons in the United States (U.S.)
passes through the CJ system annually [8], providing an opportunity to address the HIV care
continuum [3] and to deliver interventions designed to improve access to HIV care and ART.
The majority of persons involved in the U.S. criminal justice system are men, with women
representing only 7% of the prison population and up to 25% of persons on probation in the
community [9, 10]. CJ-involved women and transgender persons have unique health chal-
lenges, yet these populations remain understudied. Incarcerated women have higher rates of
substance use and addiction [11, 12], HIV infection [13, 14],hepatitis C virus infection [15],
and mental health disorders [16, 17] compared to incarcerated males [18]. Transgender per-
sons, particularly male-to-female (MTF) transgender women, experience high rates of HIV
infection [19, 20], clinical depression [21], unstable housing [22], and gender violence and eco-
nomic discrimination [23], which can contribute to risky sexual behaviors [24, 25].
Persons who cycle in and out of jails and prisons are at risk of transmitting HIV to sexual
and drug-using partners; therefore, developing and implementing interventions to improve
the delivery of HIV treatment to CJ-involved persons in order to achieve viral suppression is a
public health priority. The Seek, Test, Treat, and Retain (STTR) strategy to control the HIV
epidemic has been proposed as a public health approach to improve HIV outcomes through
greater access to ART [26–28]. The STTR strategy is multi-pronged and includes increasing
the identification of HIV-infected persons through expanded testing, linkage to HIV provid-
ers, improving access and adherence to ART, and maintaining long-term retention in care. If
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Abbreviations: CJ, criminal justice; ICT,
information and communication technology; ART,
antiretroviral treatment; MTF, male-to-female;
STTR, Seek, Test, Treat, and Retain; DC DOC,
District of Columbia Department of Corrections;
MSM, men who have sex with men.
achieved, this, in turn, decreases community transmission of HIV by creating a population of
HIV-infected persons who are less infectious by effective ART [29].
In 2010, the National Institutes of Health/National Institute on Drug Abuse funded a
research initiative to investigate the application of the STTR strategy among CJ-involved per-
sons [25]. As part of this initiative, we launched the CARE+ Corrections Study conducted in
Washington, D.C., a city with an HIV prevalence estimated to be at 2.5% of all residents and
5.8% among Black males [30]. The goal of the parent study was to develop and evaluate the
efficacy of a technology-based intervention designed to improve linkage to community HIV
providers and ART adherence following release from a correctional facility. With this inter-
vention, our study aimed to address the Treat and Retain aspects of the STTR strategy using an
intervention to leverage information and communication technology (ICT) tools. ICTs have
the potential to be scalable among correctional facilities and community partners who assist
persons released from prison or jail, also referred to as “returning citizens”. Given the gender
diversity of the CARE+ Corrections Study participants, we herein describe their baseline char-




The CARE+ Corrections Study was originally designed as a randomized, controlled, longitudi-
nal trial to evaluate the efficacy of the CARE+ Corrections intervention among a total study
population of 320 participants. However, we encountered challenges with study implementa-
tion and participant enrollment within the Washington, DC Department of Corrections (DC
DOC) facilities and were therefore unable to enroll a sufficient number of participants to eval-
uate the efficacy of the intervention. The study objective was changed to be a preliminary eval-
uation of feasibility and efficacy among 100 study participants, and enrollment was adapted to
include persons recruited inside the correctional facilities and persons in the community
recently released from a correctional facility, thus providing a convenience sample of persons
involved with the criminal justice system. Recruitment within correctional facilities was strati-
fied to ensure enrollment of at least 25% females; recruitment in the community was not strati-
fied based upon gender. Within strata, participants were randomly assigned to either the
CARE+ Corrections intervention or the control arm on a 1:1 basis using a computer-generated
randomization scheme.
Intervention and Control Groups
The CARE+ Corrections Study intervention contained two components. The first was a com-
puterized counseling session (“CARE+ Corrections”). This was an adapted version of the
CARE+ counseling tool, a one-session, interactive, computerized motivational interview that
assessed a person’s risk and HIV care behaviors (including HIV care utilization, ART adher-
ence, and retention in HIV care) and provided an individualized risk reduction plan for ART
adherence or linkage to care [31, 32, 33]. CARE+ Corrections was specifically designed to pro-
vide counseling to HIV-infected persons being released from correctional facilities. Counsel-
ing content focused on linkage to community HIV care, ART adherence, and reducing risk
behaviors [31, 34]. Participants received a printout at the end of the session that summarized
goals and provided relevant HIV treatment referrals.
The second component of the CARE+ Corrections Study intervention was scheduled text
messages to the participant following release from a correctional facility. The text messages
included supportive behavioral messaging (e.g., “One day at a time. Just for today, don’t use.”)
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as well as medication and appointment reminder messages. Participants were able to select
pre-scripted messages or create their own messages, and to select frequency and timing of mes-
saging (e.g., daily, weekly, morning, evening). All participants in the intervention group
received a cell phone and mobile service supported by the study in order to ensure the receipt
of study-based text messages.
Participants in the control group watched an educational video on opioid overdose preven-
tion and received a printout of local HIV providers and resources. The length of the video was
approximately equal to the time intervention group participants spent completing the CARE
+ Corrections counseling session. Participants in the control group did not receive a cell
phone or the text messaging intervention.
Study Population and Eligibility
The target population was HIV-infected individuals with a recent history of incarceration.
Study eligibility included being at least 18 years old, HIV-infected by self-report, incarcerated
in the DC DOC with an anticipated release date within six weeks or residing in the community
but having been released from a jail, prison or halfway house within the previous six months
(confirmed by study staff using public records), planning on remaining in the geographic area
through the end of the study period, and able to provide informed consent for study
participation.
Recruitment
Recruitment occurred in DC DOC facilities and in the community. Within DC DOC facilities,
participants were recruited in either the Central Detention Facility, which houses men and
male-to-female transgender persons, or the Correctional Treatment Facility, which houses
men and women and includes a 100-bed treatment facility for persons with substance use dis-
orders. The screening and recruitment occurred in the medical units and treatment facility of
the DC DOC where HIV care is provided by a contracted medical provider. In these locations,
study staff provided information about the study to potentially interested participants, con-
ducted eligibility assessments, and obtained written informed consent and enrolled partici-
pants. HIV-infected persons incarcerated within the DC DOC received comprehensive HIV
care including access to ART. Discharge planning services at the time of release included pro-
vision of a 30-day supply of HIV medications and a referral to community HIV providers.
Individuals from the community were recruited through a combination of street-based
recruitment, advertisement at and referrals from local community-based organizations that
provide services to returning citizens (such as the Mayor’s Office of Returning Citizens Affairs,
shelters, transitional housing programs, female and transgender-friendly agencies, and drug
treatment programs), and referrals from other study participants. Persons interested in the
study were scheduled for eligibility screening, consenting and completion of the baseline visit
at a research clinic in the community. Participants were enrolled between August 24, 2013 and
April 30, 2015, with participant follow-up continuing through December 10, 2015.
Data Collection
Although enrolled participants had follow-up assessments at 3 months and 6 months, we
report only on data collected at the baseline visit. The baseline visit included an interviewer-
administered structured assessment covering domains related to demographic characteristics,
criminal justice history, HIV care engagement, medication adherence, sexual and substance
use behaviors, and mental health and other co-morbid conditions. Participants provided a
whole blood specimen obtained by venipuncture to measure the baseline HIV plasma viral
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load (PVL) and CD4 cell count; and completed an in-depth locator form for study retention
purposes. Participants enrolled within DC DOC facilities completed the baseline appointment
over two visits so that only non-sensitive behavioral data (e.g., demographics, health care utili-
zation and medication adherence prior to current incarceration) were collected inside of the
facility. Following release, these participants were scheduled within one week of release to
complete the baseline visit (including assessment of sexual and substance use behaviors and
venipuncture for a blood specimen to conduct the HIV PVL and CD4 count). Specimens were
sent to Miriam Hospital in Rhode Island for HIV PVL testing conducted by the Roche Cobas
AmpliPrep/ Cobas Taqman HIV-1 Test, Version 2.0. CD4 cell count testing was completed by
LabCorp via the Becton Dickinson Canto II flow cytometer. When study staff were unable to
obtain blood from venipuncture or when a DOC-recruited participant did not return to com-
plete the baseline visit in the community following release, DOC or community medical rec-
ords from previous the six month period were abstracted to collect HIV PVL and CD4 count
data to establish baseline values. Informed consent for medical records abstraction was
obtained at the time of study enrollment.
Variable Definitions
Gender was defined based on a series of questions about gender identity and sex assignment
at birth. For the purposes of this analysis, a participant was designated as transgender if the
individual reported a “transgender” gender identity or if their reported gender differed from
their reported sex assignment at birth. Criminal justice experience included the length of the
most recent incarceration and the number of times ever been in jail, prison, or juvenile deten-
tion. Sexual risk behaviors in the three months prior to their most recent incarceration were
assessed, including condomless sex, exchange sex, number of sexual partners, and if designated
as male or as a transgender woman, ever and recent sex with a male partner. Substance use was
assessed for alcohol and both injection and non-injection drugs during the three months prior
to incarceration, as well as lifetime use of injection drugs. Drug dependence, categorized as
“not drug dependent” and “drug dependent”, was assessed using the TCU Drug Dependence
scale and hazardous alcohol use was determined using the WHO-AUDIT with participants
categorized as low, medium or high hazardous harmful alcohol use, both of which have been
previously validated [35, 36]. Symptoms related to post-traumatic stress disorder (PTSD) and
depression were assessed using the Primary Care PTSD Screen and the CES-D instruments,
respectively [37, 38]. In addition, participants were asked if they had even been told by a health
care provider that they had a mental health disorder diagnosis (schizophrenia, depression,
bipolar disorder, personality disorder). In addition to HIV PVL and CD4 cell count, other
HIV care indicators included having an HIV medical provider in the community (i.e., linkage
to community care) and self-reported adherence to ART 30 days prior to incarceration and
during incarceration. Adherence was measured by a visual analog scale (VAS) where partici-
pants estimated the proportion of prescribed ART doses (0–100%) taken during the previous
30 days [39]. Optimal self-reported ART adherence was defined as90%. Continuous viral
load was categorized as< 200 (undetectable) and 200 copies/mL. CD4 cell count was cate-
gorized as200 and>200 cell per uL.
Data Analysis
For this analysis, only study participants with complete baseline data were included. The analy-
sis was stratified by gender in order to assess differences among female, male, and transgender
study participants. Depending on the data distributional properties, frequencies and percent-
ages, or means and standard deviation (SD) were calculated for demographic characteristics,
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criminal justice history, sexual and substance use behaviors, healthcare utilization, and HIV
care. For categorical variables, gender differences were examined by chi-square tests or Fisher’s
exact tests, and for continuous variables, these differences were assessed by Student’s t-tests or
Wilcoxon rank sum tests. Statistical significance was set at p = 0.05, and all data management
and analyses were conducted using SAS 9.3 (Cary, NC).
Institutional Review Board Approval
This study was approved by the institutional review boards of The Miriam Hospital and The
George Washington University. Because this study included prisoners, the protocol was also
approved by the U.S. Office of Human Subjects Research Protection. A Certificate of Confi-
dentiality was obtained to further protect the responses of the study participants, and the study
was registered with ClinicalTrials.gov (NCT01721226).
Results
A total of 497 persons were pre-screened and 219 were assessed for study eligibility. Of the 112
persons who provided informed consent and were enrolled in the study, 110 completed base-
line data collection and were included in this analysis (see CONSORT flowchart in Fig 1).
Table 1 displays the demographic characteristics and site of enrollment for these partici-
pants; 70% were enrolled from the community and 30% were enrolled within the DC DOC.
Mean age was 40 (SD = 10.5), and most were Black or African American (85%). The majority
of participants were male (58%), 24% were female, and 18% were transgender, all of whom
were MTF transgender women. There were no differences across gender groups in race and
lifetime number of incarcerations (mean 10.8, SD = 9.9). The length of last incarceration was
shortest for women, at 4.8 months (SD = 11.5) compared to 19.8 months (SD = 47.4) for men
and 8.9 months (SD = 21.4) for transgender women (p<0.0001).
Table 2 displays sexual behaviors, substance use and mental health characteristics. Nearly
half (47%) of the study sample had engaged in condomless sex in the three months prior to
their last incarceration, but this did not differ across genders. However, engaging in exchange
sex was significantly higher for women and transgender women (54% and 65%, respectively)
compared to men (12%, p<0.001). Among men and transgender women, 27% of men and all
transgender women reported having had sex with a man (p<0.001), and 17% of men and 79%
of transgender women reported having anal sex with a man in the three months before their
last incarceration (p<0.001).
Drug dependence (57%), lifetime history of injection drug use (15%), recent non-injection
drug use (65%), and hazardous alcohol consumption (45%) were all highly prevalent in this
sample but did not differ across genders. However, transgender women were significantly more
likely to have participated in drug treatment compared to men and women (90% versus 61%
and 50%, respectively, p = 0.0117). In terms of mental health, depressive symptoms (52%) and
previous diagnosis of schizophrenia (23%), personality (17%) and bipolar disorders (59%), and
post-traumatic stress disorder (44%) were all highly prevalent but did not differ across genders.
Table 3 displays baseline HIV treatment and care indicators. Overall, more than 80% of
study participants had a regular HIV healthcare provider prior to their last incarceration, and
nearly all (91%) had ever taken HIV treatment. Only half (51%) indicated optimal HIV treat-
ment adherence in the 3 months prior to their last incarceration, and this did not differ by gen-
der. However, being on HIV treatment during their last incarceration was significantly lower
for women compared to men and transgender women (67% among women versus 96% and
95% among men and transgender women, respectively, p = 0.001). In addition, all transgender
women reported currently having a regular HIV provider in the community, versus 75%
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among men and 77% among women (p = 0.02). Ninety-three (88%) study participants com-
pleted phlebotomy and 13 had their medical charts reviewed for baseline HIV plasma viral
load and CD4 counts. At baseline, 80% of transgender women, 69% of men, and 48% of
women achieved HIV viral suppression (<200 copies/mL), although these differences were
not statistically significant. Women had the highest proportion of having a CD4 count200
compared to men and transgender women (5% for transgender women versus 8% for men
and 17% for women), but this also was not statistically significant.
Fig 1. CONSORT Diagram.
doi:10.1371/journal.pone.0169078.g001
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Discussion
HIV-infected persons with a history of incarceration in Washington, DC represent a vulnera-
ble population, experiencing a high frequency of lifetime arrests as well as high prevalence of
drug use, problem drinking, mental health disorders, and sexual risk behaviors. In our sample,
engagement with HIV care before and after the most recent incarceration was high among the
sample, but pre-incarceration ART adherence was sub-optimal and females had less access to
ART during their incarceration. Baseline CD4 counts were lower and viral suppression was
less frequent for women compared to males and transgender persons but these findings were
not statistically significant. ART adherence remains a challenge for persons recently involved
in the CJ system and needs to be the focus of public health efforts to reduce community viral
load.
The majority of the study population reported having access to a regular healthcare pro-
vider and HIV treatment prior to their most recent incarceration (83% and 91%, respectively);
however, only 51% reported optimal HIV treatment adherence on the VAS scale during the
three months prior to their most recent incarceration. Nearly all (89%) reported receiving HIV
treatment during their recent incarceration and 86% reported being on ART at the time the
baseline assessment was completed in the community after release; 62% had a suppressed viral
load based on objective laboratory data. This proportion of participants with viral suppression
is higher than the estimate that only 30% of HIV-infected persons in the U.S. have achieved
viral suppression; and more similar to recent studies that estimated viral suppression among
persons in HIV care [40–42]. Collectively, these data suggest that this population in Washing-
ton, DC has reliable access to HIV providers prior to, during, and after incarceration, yet ART
adherence could be improved and this would lead to higher rates of viral suppression. A recent
study demonstrated that self-report of being engaged in HIV care was not always reliable
when compared to clinic visit data [43]. Therefore, further research is needed to determine the
causes of poor ART adherence in this population and the relative contribution of missed clinic
visits. Regardless, there is a need to improve ART adherence among persons who are viremic




Enrollment location n (%) 0.1286
Community 40 (62.5) 21 (80.8) 16 (80.0) 77 (70.0)
DC Department of Corrections 24 (37.5) 5 (19.2) 4 (20.0) 33 (30.0)
Race/Ethnicity n (%) 0.7504
Black/African American 56 (87.5) 21 (80.8) 17 (85.0) 94 (85.5)
White 1 (1.6) 2 (7.7) 1 (5.0) 4 (3.6)
Hispanic 1 (1.6) 0 (0.0) 0 (0.0) 1 (0.9)
Other 6 (9.4) 3 (11.5) 2 (10.0) 11 (10.0)
Age—Mean (SD) 42 (10.7) 39 (9.2) 35 (9.4) 40 (10.5) 0.0251
Sexual orientation n (%) 0.0023
Heterosexual or straight 51 (79.7) 24 (92.3) 9 (45.0) 84 (76.4)
Homosexual, gay or lesbian 8 (12.5) 1 (3.9) 9 (45.0) 18 (16.4)
Bisexual 5 (7.8) 1 (3.9) 2 (10.0) 8 (7.3)
Length of last incarceration, months—Mean (SD) 19.8 (47.4) 4.8 (11.5) 8.9 (21.4) 14.3 (38.3) < .0001
Number of times in jail/prison, lifetime—Mean (SD) 10.3 (8.6) 11.8 (13.2) 10.7 (8.5) 10.8 (9.9) 0.9067
Bold text indicates p<0.05.
doi:10.1371/journal.pone.0169078.t001
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n (%) n (%) n (%) n (%)
Any condomless sex in 3 mo before last incarceration 0.6443
No 34 (53.1) 12 (46.2) 12 (60.0) 58 (52.7)
Yes 30 (46.9) 14 (53.9) 8 (40.0) 52 (47.3)
Ever had sex with a man (among men and transgender)1 < .0001
No 47 (73.4) 0 (0.0) 0 (0.0) 47 (56.6)
Yes 17 (26.6) 0 (0.0) 19 (100.0) 36 (43.4)
Had anal sex with man in 3 mo before last incarceration1 < .0001
No 53 (82.8) 0 (0.0) 4 (27.1) 57 (68.7)
Yes 11 (17.2) 0 (0.0) 15 (79.0) 26 (31.3)
Exchange sex in 3 mo before last incarceration < .0001
No 56 (87.5) 12 (46.2) 7 (35.0) 75 (68.2)
Yes 8 (12.5) 14 (53.9) 13 (65.0) 35 (31.8)
Drug Dependence (TCU score) (12 mo before last incarceration) 0.8070
No 29 (45.3) 10 (38.5) 8 (40.0) 47 (42.7)
Yes 35 (54.7) 16 (61.5) 12 (60.0) 63 (57.3)
Ever injected drugs 0.1832
No 51 (79.7) 24 (92.3) 19 (95.0) 94 (85.5)
Yes 13 (20.3) 2 (7.7) 1 (5.0) 16 (14.6)
Non-injection drug use in 3 mo before last incarceration2 0.1384
No 22 (37.3) 10 (43.5) 2 (13.3) 34 (35.1)
Yes 37 (62.7) 13 (56.5) 13 (86.7) 63 (64.9)
Ever been in drug treatment 0.0117
No 25 (39.1) 13 (50.0) 2 (10.0) 40 (36.4)
Yes 39 (60.9) 13 (50.0) 18 (90.0) 70 (63.6)
Alcohol use (WHO AUDIT) 0.2825
Low hazardous or harmful alcohol use 30 (46.9) 17 (65.4) 14 (70.0) 61 (55.5)
Medium hazardous or harmful alcohol use 13 (20.3) 3 (11.5) 1 (5.0) 17 (15.5)
High hazardous or harmful alcohol use 21 (32.8) 6 (23.1) 5 (25.0) 32 (29.1)
Depressive symptoms (CESD-10) 0.7904
No 32 (50.0) 11 (42.3) 10 (50.0) 53 (48.2)
Yes 32 (50.0) 15 (57.7) 10 (50.0) 57 (51.8)
Ever diagnosed with schizophrenia3 0.5195
No 51 (81.0) 17 (65.4) 16 (80.0) 84 (77.1)
Yes 12 (19.0) 9 (34.6) 4 (20.0) 25 (22.9)
Ever diagnosed with personality disorder3 0.4152
No 55 (87.3) 19 (73.1) 16 (80.0) 90 (82.6)
Yes 8 (12.7) 7 (26.9) 4 (20.0) 19 (17.4)
Ever diagnosed with bi-polar/manic depression3 0.3946
No 28 (43.8) 9 (34.6) 8 (42.1) 45 (41.3)
Yes 36 (56.3) 17 (65.4) 11 (57.9) 64 (58.7)
Positive screen for PTSD 0.7444
No 37 (57.8) 13 (50.0) 12 (60.0) 62 (56.4)
Yes 27 (42.2) 13 (50.0) 8 (40.0) 48 (43.6)
1. N = 83.
2. Of those who reported ever using non-injection drugs (N = 97).
3. N = 109.
Bold text indicates p<0.05.
doi:10.1371/journal.pone.0169078.t002
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and have concurrent risk behaviors given that they may transmit HIV to sex and drug using
partners, supporting the premise that this is a high priority population for intervention.
The relatively large proportions of transgender women and men who have sex with men
(MSM) that were recruited into the study was not anticipated. These groups, particularly HIV-
infected MSM and transgender women, remain largely hidden within correctional populations
and few studies have estimated their prevalence. The multi-site Enhance Link Initiative
enrolled over 1200 HIV-infected persons with a history of jail incarceration and among these,
20% identified as MSM or bisexual [44], which was consistent with the proportion observed in
our study. These findings and our results suggest that HIV-infected MSM, bisexuals, and
transgender women may represent a larger proportion of HIV-infected persons behind bars
than previously recognized. More research is needed to understand the epidemiology, risk
profiles, and unique barriers to health services that these persons are likely to encounter in the
coercive and highly stigmatized environment of correctional facilities.
The study revealed some important gender differences among our study population.
Women exhibited worse outcomes compared to both men and transgender women, which is




n (%) n (%) n (%) n (%)
Had regular healthcare provider pre-incarceration 0.2065
No 14 (21.9) 4 (15.4) 1 (5.0) 19 (17.3)
Yes 50 (78.1) 22 (84.6) 19 (95.0) 91 (82.7)
Ever been on HIV treatment 0.9013
No 7 (10.9) 2 (7.7) 1 (5.0) 10 (9.1)
Yes 57 (89.1) 24 (92.3) 19 (95.0) 100 (90.9)
HIV treatment adherence in 30 days before last incarceration1 0.3403
0%-80% 23 (56.1) 6 (40.0) 6 (37.5) 35 (48.6)
90%-100% 18 (43.9) 9 (60.0) 10 (62.5) 37 (51.4)
Took HIV treatment during incarceration2 0.0011
No 2 (3.5) 8 (33.3) 1 (5.3) 11 (11.0)
Yes 55 (96.5) 16 (66.7) 18 (94.7) 89 (89.0)
Currently have regular HIV healthcare provider 0.0245
No 16 (25.0) 6 (23.1) 0 (0.0) 22 (20.0)
Yes 48 (75.0) 20 (76.9) 20 (100.0) 88 (80.0)
Currently taking HIV treatment 0.9306
No 9 (14.1) 4 (15.4) 2 (10.0) 15 (13.6)
Yes 55 (85.9) 22 (84.6) 18 (90.0) 95 (86.4)
Baseline Viral Load3 0.0614
<200 copies/mL 42 (68.9) 12 (48.0) 16 (80.0) 70 (66.0)
 200 copies/mL 19 (31.1) 13 (52.0) 4 (20.0) 36 (34.0)
Baseline CD4 Count4 0.4229
200 cells/uL 5 (8.2) 4 (16.7) 1 (5.0) 10 (9.5)
>200 cells/uL 56 (91.8) 20 (83.3) 19 (95.0) 95 (90.5)
1. Of those on HIV treatment before last incarceration (N = 72).
2. Of those reporting ever on HIV treatment (N = 100).
3. N = 106.
4. N = 105.
Bold text indicates p<0.05.
doi:10.1371/journal.pone.0169078.t003
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consistent with the literature [16, 17, 45, 46]. Women in our study were less likely to receive
ART during their incarceration compared to men and transgender women and were least
likely to have viral suppression at the baseline assessment. Being less likely to receive treatment
during the recent incarceration may have been mediated by having shorter incarcerations.
Women in our sample receiving ART had longer incarceration periods (3.38 months,
SD = 2.14) compared to women who did not receive ART (mean = 0.74 months, SD = 2.14)
(p = 0.003). Prior research has found that acceptance of ART in a correctional facility among
women can be affected by stigma, perceived trust of a provider, and satisfaction of care [47],
but there are few studies surrounding these issues and results are inconclusive. For example,
contrary to our findings, another study found that even with shorter incarcerations, women
were more likely to achieve viral suppression during incarceration compared to men [46].
More research is needed to understand acceptability of ART in a correctional setting and if
shorter incarceration periods impose structural barriers (e.g., waiting to be seen by a provider)
that reduce access to ART among women. This difference in access to ART is important
because it is well documented that women, on average, serve shorter sentences compared to
men [48].
Transgender women in our sample were more likely to have an HIV care provider prior to
incarceration and at the baseline visit compared to both men and women. The reasons for
these findings remain unclear, yet this is encouraging given other studies have shown HIV-
infected transgender women to have poorer access to care including ART and a greater num-
ber of social and structural barriers to care [49–55]. Our findings suggest qualitative research
is needed to identify both facilitators and barriers to HIV care and ART among transgender
persons who have a history of incarceration.
Our study had several limitations. The generalizability of our findings to other correctional
populations is limited by several factors: the sample size was small and therefore lowered the
power to detect significant differences between gender groups that may have existed; the study
population was relatively homogeneous in terms of race (85% were Black/ African-American);
and one-half of study participants received a phone which may have prevented some persons
from enrolling given there was a 50% chance of not receiving a phone. We opted to recruit
study participants from the DC DOC facilities and from the community following release due
to difficulty in launching recruitment inside of the DC DOC. This resulted in a more heteroge-
neous population that may differ with respect to HIV care and risk behaviors. However, there
were few significant differences in risk behaviors by enrollment site, and no significant differ-
ences in demographic characteristics or HIV care (data not shown). Community recruitment
largely occurred through social support agencies that supported returning citizens. This may
have introduced some selection bias favoring HIV-infected persons who were engaged with
these agencies; however, we also recruited through street-outreach in an effort to enroll a more
representative population of returning citizens. Our analysis of baseline viral suppression
included both laboratory testing conducted by the study and PVL data obtained from medical
chart review, which increased the variability of length of time between study entry and as-
sessment of viral suppression. Despite these limitations, this analysis represents a unique
examination of HIV care and risk behaviors among recently incarcerated persons, including
transgender women.
Conclusions
Improving HIV treatment outcomes among CJ-involved persons is an important component
to the broader STTR strategy given the vulnerability of this population and the fact that the
vast majority of incarcerated HIV-infected persons eventually return to their communities.
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Our findings emphasize that improving ART adherence among CJ-involved persons remains
a high priority for intervention, particularly among CJ-involved women who are at greatest
risk of poor HIV outcomes. Differences in HIV care indicators and risk behaviors among
men, women, and transgender women further support the need for additional research to
develop gender-specific interventions to address the unique needs of each group.
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